Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and energy, preventing protein catabolism and ketosis. Sodium chloride maintains osmotic pressure and fluid balance. Potassium chloride replenishes potassium and maintains intracellular ion gradients.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA: Source of water, electrolytes, and calories for parenteral nutrition when oral intake is not possible,Off-label: Treatment of hypokalemia, maintenance fluid therapy
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric needs. Typical adult maintenance: 100-125 m L/hour (2-3 L/day) of D5 0.2% Na Cl with 0.15% KCl (20 m Eq KCl/L) administered via continuous IV infusion.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Dextrose: Not applicable (endogenous substrate, rapidly cleared via metabolism). Potassium: Terminal elimination half-life ~12-24 hours in healthy individuals, prolonged in renal impairment. Sodium and chloride: No defined half-life; renal excretion is regulated by homeostatic mechanisms.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the Krebs cycle. Sodium chloride and potassium chloride are not metabolized; they are excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: Dextrose is completely metabolized to CO2 and water; only trace amounts excreted unchanged (<2%). Sodium and chloride are primarily excreted renally, with >90% of filtered load reabsorbed; excess is excreted in urine. Potassium is predominantly excreted renally (90%), with minor fecal (10%) loss. Biliary excretion is negligible.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: Negligible (<1%). Sodium: Negligible. Chloride: Negligible. Potassium: Negligible. No specific binding proteins.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: 0.2-0.3 L/kg (mainly extracellular fluid). Sodium: 0.6-0.7 L/kg (total body water). Chloride: 0.4-0.5 L/kg (extracellular fluid). Potassium: 3-5 L/kg (primarily intracellular; Vd large due to active transport into cells).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%. Oral: Not applicable (solution is for IV use only).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
For GFR <30 m L/min: use with caution; reduce potassium content as needed based on serum potassium levels; avoid if anuria or severe renal impairment. No specific dose adjustment for the dextrose/saline component, but consider total volume and electrolyte content.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A: no adjustment. Class B or C: monitor serum potassium and glucose; consider reducing potassium if hyperkalemia risk; no specific dose change required but infusion rate may need adjustment based on fluid tolerance.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based: 0.2% Na Cl with 0.15% KCl in 5% dextrose. Rate: 100-150 m L/kg/day for maintenance; adjust based on age, weight, and clinical condition. Potassium: 1-2 m Eq/kg/day, not to exceed 3 m Eq/kg/day. Administer via IV infusion.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients: use with caution due to potential renal impairment and reduced cardiac reserve. Monitor serum potassium and renal function closely. Infusion rates should be conservative, generally lower than younger adults, with careful attention to fluid balance to avoid overload.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with anuria. Potassium-containing solutions should not be used in patients with severe renal impairment or hyperkalemia.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Monitor serum electrolytes, including potassium and sodium, and blood glucose levels,Risk of hyperkalemia, especially in patients with renal impairment or those receiving potassium-sparing diuretics,Avoid fluid overload in patients with heart failure or renal impairment,Use with caution in patients with diabetes mellitus or glucose intolerance
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Severe renal impairment (anuria or oliguria),Addison's disease,Severe burns or trauma,Solutions containing dextrose may be contraindicated in patients with known allergy to corn
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, patients with renal impairment may require dietary potassium and sodium restrictions. Avoid high-potassium foods if hyperkalemia is a concern.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic risk is expected at physiological doses. Inadvertent excessive administration leading to electrolyte imbalances may pose indirect fetal risks (e.g., hyperkalemia causing fetal arrhythmias). Use during pregnancy only if clearly needed and with monitoring.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Dextrose, sodium, and potassium are normal constituents of breast milk. IV administration at standard doses does not significantly alter milk composition. M/P ratio not applicable; use during lactation is considered safe.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustment required for pregnancy-related pharmacokinetic changes; standard dosing based on clinical need and electrolyte monitoring.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Avoid in severe hyperkalemia, hypernatremia, or fluid overload. Use cautiously in patients with renal impairment or heart failure. Monitor serum potassium and glucose levels during prolonged infusion. Do not administer via same line as blood products due to risk of hemolysis.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Inform your healthcare provider if you have a history of heart failure, kidney disease, or diabetes.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,Do not adjust the infusion rate yourself; it is set by the healthcare professional.,Tell your doctor if you are pregnant or breastfeeding.,This solution contains potassium; do not take extra potassium supplements without consulting your doctor.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and energy, preventing protein catabolism and ketosis. Sodium chloride maintains osmotic pressure and fluid balance. Potassium chloride replenishes potassium and maintains intracellular ion gradients.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric needs. Typical adult maintenance: 100-125 m L/hour (2-3 L/day) of D5 0.2% Na Cl with 0.15% KCl (20 m Eq KCl/L) administered via continuous IV infusion.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic risk is expected at physiological doses. Inadvertent excessive administra. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.